Equity Overview
Price & Market Data
Price: $1.71
Daily Change: +$0.03 / 1.75%
Daily Range: $1.66 - $1.77
Market Cap: $12,312,664
Daily Volume: 619
Performance Metrics
1 Week: 6.37%
1 Month: -16.50%
3 Months: -7.73%
6 Months: -41.81%
1 Year: -56.51%
YTD: 1.21%
Company Details
Employees: 12
Sector: Health technology
Industry: Biotechnology
Country: Israel
Details
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv-Yafo, Israel.